CAS: 7789-33-5; Iodine Monobromide

上下游产品

bromine iodine bromopentafluoroethane iodidemanganese(II) bromide nickel dibromide bismuth(III) bromide germanium tetrabromide

一氯化碘置于sea-Salt体系中,用 Neat (No Solvent) 作为反应溶剂,化学反应生成 一溴化碘
参考文献:Hoi与卤化钠盐的非均相反应
标题:Hoi与卤化钠盐的非均相反应
摘要:气态 Hoi 与 Nacl 和海盐的晶粒以及 Nabr 晶体薄膜的相互作用已在与四极质谱仪耦合的壁涂层管式流动反应器中进行了研究,浓度范围为 (0.2-8) x 1012 分子 Cm-3置于278 和 298 K.在新鲜表面上,确定的吸收系数与温度无关,分别为 Nabr,Nacl 和海盐的 γ = 0.034 +/-0.009,γ = 0.016 +/-0.004 和 γ = 0.061 +/-0.021 .置于278 K 时,在 0 和 23% 相对湿度之间添加水蒸气时没有观测到反应性增加.还表明盐表面的反应性随着暴露于 Hoi 的时间而降低,并且稳态吸收在"老化"的盐表面.释放到气相中的反应产物是 Ibr,Icl,和 Ibr + Icl 分别用于 Hoi置于nabr,Nacl 和海盐表面上的反应.简要讨论了所得结果的大气影响.
DOI:10.1021/jp0044678

专利信息

专利号:US-8269001-B2
优先权日:2005-10-05
标题 :Process for the synthesis of HMG-CoA reductase inhibitors
发明人：CASAR ZDENKO
权利人:CASAR ZDENKO; LEK PHARMACEUTICALS
摘要:A novel synthesis of statins uses Wittig reaction of a heterocyclic core of statin with a lactonized side chain already possessing needed stereochemistry. Any separation of diastereoisomers is performed early in the course of synthesis.

专利号:US-2023220001-A1
优先权日:2020-06-09
标 题:Method for synthesis of thioether-containing peptides
发明人：GRUSS HENDRIK; LUTZ CHRISTIAN; SÃœSSMUTH RODERICH; Yao guiyang; KNITTEL CAROLINE; KOSOL SIMONE; MAINZ ANDI
权利人:HEIDELBERG PHARMA RES GMBH
摘要:The present invention relates to a method of formation of a sulphur bridge between tryptophan and cysteine in solid phase peptide synthesis under iodine treatment. The invention also relates to the resulting compounds of the method and their respective use.

专利号:US-8933181-B2
优先权日:2006-10-06
标题:Branched polymers and methods for their synthesis and use
发明人：MOURI HIROSHI; LUO STEVEN; KURASCH JESSICA; ROBERTSON CHRISTOPHER G; WARREN SANDRA
权利人:MOURI HIROSHI; LUO STEVEN; KURASCH JESSICA; ROBERTSON CHRISTOPHER G; WARREN SANDRA; BRIDGESTONE CORP
摘要:Branched polymers including multi-branched polymers, functionalized branched polymers, star-branched polymers, and dendigraft polymers. Methods for the synthesis of branched polymers and method for the use of branched polymers in tire components are also included.

专利号:US-7705159-B2
优先权日:2005-07-06
标题:Process for the preparation of letrozole
发明人：MACDONALD PETER LINDSAY; BIGATTI ETTORE; ROSSETTO PIERLUIGI; HAREL ZVI
权利人:SICOR INC
摘要:The invention provides a high-yield process for the preparation of letrozole having a high purity, without the need for removal of the 4-[1-(1,3,4-triazolyl)methyl]benzonitrile impurity at the intermediate stage. The invention also provides a process for the synthesis of letrozole in which formation of the impurity 4-[1-(1,3,4-triazolyl)methyl]benzonitrile during the first stage is minimized. In the process, a 4-(halomethyl)benzonitrile is reacted with a salt of 1H-1,2,4-triazole, reducing the formation of the impurity. Preferably, the preparation is conducted as a one-pot process.

专利号:WO-2024168123-A1
优先权日:2023-02-09
标 题 :Synthesis of core 2 o-sialyl lewis-x polysaccharides
发明人：CHAIKOF ELLIOT; DHAKAL BIBEK; MANDHAPATI APPI; ERADI PRADHEEP
权利人:BETH ISRAEL DEACONESS MEDICAL CT INC
摘要:Provided herein are methods and compounds useful in the preparation of Core 2 O -sialyl Lewis x polysaccharides including compounds of Formula (C).

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.